The Latest Breast Cancer Industry Statistics Explained
Each year, breast cancer is responsible for more than 400,000 deaths in women globally.
The statistic that each year, breast cancer is responsible for more than 400,000 deaths in women globally highlights the significant impact of this disease on women’s health worldwide. Breast cancer is one of the most common types of cancer affecting women, and its high mortality rate emphasizes the importance of early detection, diagnosis, and treatment. This statistic underscores the urgent need for improved access to healthcare services, increased awareness about breast cancer prevention and screening, and ongoing research efforts to develop more effective treatment options to reduce the number of deaths caused by this devastating disease.
The global breast cancer therapeutics market size was valued at USD 17.2 billion in 2019.
This statistic indicates that the global breast cancer therapeutics market generated revenue amounting to USD 17.2 billion in the year 2019. This figure represents the total value of sales of medications, treatments, and therapies specifically targeting the treatment of breast cancer on a worldwide scale during that year. The substantial market size underscores the significant demand and expenditure on breast cancer therapeutics, reflecting the high prevalence of breast cancer cases globally and the importance placed on developing and accessing effective treatments for this disease. This statistic serves as a crucial indicator for stakeholders, including pharmaceutical companies, healthcare providers, policymakers, and investors, to understand the market landscape and opportunities within the breast cancer therapeutics sector.
North America commanded the largest share of the breast cancer treatment market.
This statistic indicates that North America constitutes the highest proportion of the breast cancer treatment market compared to other regions globally. The phrase “commanded the largest share” suggests that North America dominates in terms of market presence or revenue generation within the breast cancer treatment industry. This could be due to various factors such as advanced healthcare infrastructure, higher prevalence of breast cancer in the region, greater awareness and access to healthcare services, and possibly the presence of leading pharmaceutical companies or research institutions focusing on breast cancer treatments. Consequently, this statistic highlights North America as a significant player in the breast cancer treatment market, with implications for healthcare policies, funding, research, and patient outcomes in the region.
By 2025, the worldwide breast cancer treatment market is projected to reach USD 38.6 billion.
The statistic “By 2025, the worldwide breast cancer treatment market is projected to reach USD 38.6 billion” indicates the estimated total value of sales related to breast cancer treatment products and services worldwide by the year 2025. This figure reflects the anticipated growth and demand for treatments, therapies, medications, diagnostic tools, and other healthcare services specifically targeting breast cancer. The projected value is a key indicator for healthcare professionals, policymakers, investors, and stakeholders involved in the breast cancer treatment industry, providing insights into the market scale, trends, and potential opportunities for advancements in research, development, and access to care for individuals affected by breast cancer globally.
Trastuzumab accounted for the largest market share in 2019 in breast cancer therapies.
The statistic “Trastuzumab accounted for the largest market share in 2019 in breast cancer therapies” indicates that Trastuzumab, a targeted therapy commonly used in the treatment of HER2-positive breast cancer, was the most frequently prescribed and widely utilized medication among available options for breast cancer treatment in 2019. This suggests that Trastuzumab was the preferred choice of healthcare providers and patients, potentially due to its proven effectiveness in improving outcomes for this specific subtype of breast cancer. The high market share highlights the significance of Trastuzumab as a prominent and valuable therapeutic option in the management of breast cancer, reflecting its impact on clinical practice and patient care during that period.
In 2021, an estimated 2,81,550 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S.
This statistic indicates that in the year 2021, it is projected that approximately 281,550 new cases of invasive breast cancer will be diagnosed among women in the United States. Invasive breast cancer refers to cancer that has spread from where it began in the breast into surrounding healthy tissues. This statistic highlights the significant burden of breast cancer on women in the U.S. and underscores the importance of early detection, regular screenings, and access to quality healthcare for timely diagnosis and treatment to improve outcomes and reduce mortality rates associated with this prevalent form of cancer.
113.2 per 100,000 women per year is the incidence rate of breast cancer in women.
The statistic ‘113.2 per 100,000 women per year is the incidence rate of breast cancer in women’ indicates the rate at which new cases of breast cancer are diagnosed in a specific population over a one-year period. This figure represents the number of new cases of breast cancer diagnosed per 100,000 women in that population over the course of a year. A higher incidence rate suggests a greater risk of developing breast cancer within that population. This statistic is crucial in understanding the burden of breast cancer and assessing the need for preventive measures, screening programs, and treatment resources for women at risk in the population.
The breast cancer testing market is expected to grow at a CAGR of 11.6% from 2021 to 2025.
This statistic indicates that the breast cancer testing market is projected to increase steadily at a compounded annual growth rate (CAGR) of 11.6% between the years 2021 and 2025. A CAGR provides a more accurate representation of the growth rate over multiple time periods compared to a simple annual growth rate. The 11.6% CAGR suggests a strong and consistent expansion in the market demand for breast cancer testing services and products over the specified timeframe. This growth could be driven by factors such as advancements in technology, increasing awareness about early detection, and rising prevalence of breast cancer worldwide, leading to a higher demand for testing and screening solutions.
The global market for breast cancer liquid biopsy is expected to reach USD 642.9 million by 2026.
This statistic indicates the projected growth and size of the global market for breast cancer liquid biopsy testing by the year 2026, with an estimated value of USD 642.9 million. Breast cancer liquid biopsy is a non-invasive method of detecting and monitoring cancer through the analysis of biomarkers in blood or other bodily fluids. The increasing adoption of liquid biopsy techniques for early detection, treatment monitoring, and personalized medicine in breast cancer patients is expected to drive the significant market expansion. The growing awareness of the benefits of liquid biopsy over traditional tissue biopsy, such as its minimally invasive nature and ability to capture tumor heterogeneity, is likely to contribute to the market’s substantial growth in the coming years.
Europe accounted for the second largest share of the breast cancer therapeutic market.
The statistic “Europe accounted for the second largest share of the breast cancer therapeutic market” indicates that among all regions, Europe ranked second in terms of the proportion of sales or revenue generated from breast cancer therapeutic products or services. This suggests that Europe plays a significant role in the breast cancer treatment market, with a substantial share of the market being attributed to patients in this region. Factors such as population size, healthcare infrastructure, research and development initiatives, and patient access to treatments may contribute to Europe’s strong position in the breast cancer therapeutic market. Understanding these regional variations can help stakeholders tailor their strategies to effectively address the needs and demands of the European breast cancer patient population.
The five-year survival rate for women with invasive breast cancer is 91%.
The statistic ‘The five-year survival rate for women with invasive breast cancer is 91%’ represents the percentage of women diagnosed with invasive breast cancer who are expected to be alive five years after their initial diagnosis. This specific statistic indicates a high level of overall survival among women with this type of cancer, with 91 out of every 100 women living beyond the five-year mark. A high five-year survival rate is generally considered indicative of early detection, effective treatment options, and advancements in healthcare. However, it is important to note that individual outcomes can vary based on factors such as the stage of cancer at diagnosis, treatment received, and overall health of the patient.
Breast cancer represents 15.5% of all new cancer cases in the United States.
The statistic that breast cancer represents 15.5% of all new cancer cases in the United States indicates the proportion of newly diagnosed cancer cases that are attributed to breast cancer. This statistic highlights the significant burden of breast cancer in the United States compared to other types of cancer. The 15.5% figure underscores the prevalence and importance of breast cancer screening, early detection, and treatment efforts to address this major health issue. Understanding the distribution of cancer types can inform healthcare policy, resource allocation, and research priorities to improve outcomes for individuals affected by breast cancer and advance cancer prevention and control strategies within the country.
The Asia-Pacific breast cancer diagnostic market is anticipated to witness the fastest growth, at a CAGR of 13.7% during 2021-2028.
This statistic indicates that the Asia-Pacific breast cancer diagnostic market is projected to experience substantial growth over the period from 2021 to 2028, with a compound annual growth rate (CAGR) of 13.7%. This implies that the market for breast cancer diagnostic technologies and services in the Asia-Pacific region is expected to expand rapidly during the forecast period. Factors driving this growth may include increasing awareness about breast cancer, improving healthcare infrastructure, rising healthcare spending, and advancements in diagnostic technologies. The high growth rate suggests significant opportunities for companies operating in this market to expand their presence and offer innovative solutions to meet the growing demand for breast cancer diagnostic services in the Asia-Pacific region.
An estimated 45,000 deaths will occur in the US due to breast cancer in 2021.
The statistic “An estimated 45,000 deaths will occur in the US due to breast cancer in 2021” represents a projection of the number of individuals in the United States who are expected to lose their lives as a direct result of breast cancer in the year 2021. This statistic highlights the significant impact that breast cancer continues to have on the population, emphasizing the urgent need for increased awareness, early detection, and improved treatment options to reduce the mortality rate associated with this disease. The estimated number of deaths serves as an important indicator for public health officials, healthcare providers, and policymakers to prioritize resources and initiatives aimed at improving outcomes for individuals affected by breast cancer.
The breast cancer therapeutics market in Latin America is expected to grow at a CAGR of 13.5% during the forecast period.
This statistic indicates the expected growth rate of the breast cancer therapeutics market in Latin America over a specified forecast period. The Compound Annual Growth Rate (CAGR) of 13.5% suggests that the market is projected to expand steadily at an average annual rate of 13.5%. This growth rate reflects an increasing demand for breast cancer treatment options in the region, likely driven by factors such as rising awareness, improving healthcare infrastructure, and advancements in medical technology. Stakeholders in the breast cancer therapeutics market can use this statistic to assess potential investment opportunities and make strategic decisions to capitalize on the expected growth in Latin America.
The global breast cancer imaging market is expected to reach USD 6.8 billion by 2027.
The statistic states that the global breast cancer imaging market, which includes various imaging technologies such as mammography, ultrasound, MRI, and others used for the detection and monitoring of breast cancer, is projected to reach a market value of USD 6.8 billion by the year 2027. This growth is driven by factors such as rising prevalence of breast cancer worldwide, increasing awareness and screening programs, technological advancements in imaging modalities, and improved healthcare infrastructure in developing countries. The increasing focus on early detection and personalized treatment strategies for breast cancer is expected to further propel the demand for breast cancer imaging technologies, ultimately leading to the forecasted market size of USD 6.8 billion by 2027.
The breast cancer monoclonal antibodies market is expected to reach USD 18.9 billion by 2025.
This statistic indicates the anticipated size of the breast cancer monoclonal antibodies market in terms of revenue by the year 2025. The projection of USD 18.9 billion suggests a substantial growth potential for this sector, driven by factors such as increasing prevalence of breast cancer worldwide, advancements in monoclonal antibody therapies, and rising investments in research and development. The growth forecast highlights the expanding market opportunities for companies involved in developing and commercializing monoclonal antibodies for the treatment of breast cancer, as well as the growing demand for more targeted and effective therapies in the oncology field.
Hormone receptor (HR) positive cancer type segment accounted for the largest revenue share in 2019, which was over 60% in the breast cancer therapeutics market.
This statistic indicates that in 2019, hormone receptor (HR) positive cancer type segment was the predominant contributor to the revenue generated in the breast cancer therapeutics market, claiming a market share exceeding 60%. This suggests that treatments targeting HR-positive breast cancer were the most commonly prescribed or utilized among healthcare providers and patients. The high revenue share attributed to this cancer type segment underscores its clinical significance and prevalence within the market, potentially reflecting the effectiveness or popularity of therapies tailored specifically for HR-positive breast cancer. This information is crucial for understanding market dynamics, treatment trends, and the importance of personalized medicine approaches in managing breast cancer.
The 5-year relative survival rate from 2011 to 2017 for male breast cancer is 84%.
The 5-year relative survival rate of 84% for male breast cancer from 2011 to 2017 indicates the proportion of males diagnosed with breast cancer during this time period who were still alive five years after their diagnosis, relative to the general population. In other words, about 84% of males diagnosed with breast cancer between 2011 and 2017 were still alive five years later. This statistic provides insight into the overall prognosis and effectiveness of treatments for male breast cancer during this time frame, highlighting a relatively high survival rate and potentially improvements in early detection and treatment strategies.
In 2019, there were an estimated 168,292 women living with breast cancer in the UK.
The statistic “In 2019, there were an estimated 168,292 women living with breast cancer in the UK” indicates the approximate number of women in the United Kingdom who were diagnosed with and currently living with breast cancer during that year. This statistic highlights the significant impact of breast cancer on women’s health in the UK and underscores the importance of continued research, awareness, and support for those affected by this disease. It serves as a critical data point for healthcare professionals, policymakers, and advocacy groups to understand the scope of the issue and allocate resources effectively to improve prevention, diagnosis, and treatment strategies for breast cancer in the UK.
References
0. – https://www.www.marketsandmarkets.com
1. – https://www.www.cdc.gov
2. – https://www.www.who.int
3. – https://www.markets.businessinsider.com
4. – https://www.www.gminsights.com
5. – https://www.www.cancer.net
6. – https://www.www.alliedmarketresearch.com
7. – https://www.www.cancerresearchuk.org
8. – https://www.seer.cancer.gov
9. – https://www.www.transparencymarketresearch.com
10. – https://www.www.cancer.org
11. – https://www.www.breastcancer.org
12. – https://www.www.grandviewresearch.com
13. – https://www.www.mordorintelligence.com
